Ethics committee of drug clinical trials of huazhong university of science and technology
Wuhan, Hubei, 430030, China
NCT Number: NCT04162821
To evaluate the pharmacokinetic characteristics of hydronidone capsules (specification: 30 mg/ pill) in healthy subjects And the effect of feeding on pharmacokinetics to provide evidence for phase II/III clinical trial protocols.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Wuhan, Hubei, 430030, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Take hydroxynitone capsule
Time frame: up to 12 weeks
Plasma drug concentration after administration of different doses of hydronidone
Beijing Continent Pharmaceutical Co, Ltd.
Industry
Clinical Pharmacokinetics of Hydroxynitone Capsules in Healthy Chinese Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.